- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | Cantor Fitzgerald bestätigt "Übergewichten"-Rating für Lexeo Therapeutics | 6 | Investing.com Deutsch | ||
| LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 31.03. | Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating | 3 | Investing.com | ||
| 30.03. | Lexeo Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 30.03. | Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights | 110 | GlobeNewswire (Europe) | SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness... ► Artikel lesen | |
| 05.02. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.01. | Lexeo Therapeutics stellt Führungsteam neu auf und ernennt Chief Medical Officer | 1 | Investing.com Deutsch | ||
| 27.01. | Lexeo Therapeutics announces key leadership appointments | 1 | Investing.com | ||
| 27.01. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.01. | Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock | 9 | Investing.com | ||
| 13.01. | Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating | 1 | Investing.com | ||
| 13.01. | H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns | 3 | Investing.com | ||
| 12.01. | Aktie von Lexeo Therapeutics bricht nach Studiendaten zur Gentherapie ein | 5 | Investing.com Deutsch | ||
| 12.01. | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.01. | Lexeo: Positive Studiendaten zu Gentherapie bei Herzerkrankung | 3 | Investing.com Deutsch | ||
| 12.01. | Lexeo's gene therapy shows promising results for heart condition | 3 | Investing.com | ||
| 12.01. | Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy | 217 | GlobeNewswire (Europe) | LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across participants... ► Artikel lesen | |
| 08.01. | Lexeo Therapeutics Partners With JNJ To Investigate Localized Cardiac Delivery Of Gene Therapy | 451 | AFX News | NEW BRUNSWICK (dpa-AFX) - Lexeo Therapeutics, Inc. (LXEO), Thursday announced a research collaboration with Johnson & Johnson (JNJ) to investigate localized cardiac delivery of gene therapy.Under... ► Artikel lesen | |
| 08.01. | Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy | 221 | GlobeNewswire (Europe) | Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson's expertise in cardiovascular therapeutics and circulatory technologies, including Impella heart pumps... ► Artikel lesen | |
| 27.12.25 | Wall Street Rallies Behind Lexeo Therapeutics (LXEO)'s Gene Therapy Pipeline | 3 | Insider Monkey | ||
| 17.12.25 | Raymond James initiates Lexeo Therapeutics stock with Strong Buy rating | 4 | Investing.com |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,810 | +3,31 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen | |
| ILLUMINA | 102,88 | -0,23 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| BRAIN BIOTECH | 2,470 | +1,23 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Patent
BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie
23.03.2026 / 11:05 CET/CEST
Für... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,227 | +2,90 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results |
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,160 | +0,02 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 26.03.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 26.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 26.03.2026.ISIN NameCA2568277834 DOLLY... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 7,025 | +3,54 % | Emergent BioSolutions wird Lieferant für Naloxon-Programm in British Columbia | ||
| DENALI THERAPEUTICS | 16,305 | -0,55 % | Takeda tears up Denali partnership, returning dementia asset amid restructuring | ||
| TRAWS PHARMA | 1,480 | -1,33 % | Traws Pharma, Inc.: Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal ... | Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID- with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution... ► Artikel lesen | |
| UNIQURE | 13,380 | +1,98 % | uniQure Inc.: uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease | LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen | |
| CAPRICOR | 26,140 | -1,73 % | Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California | COSTA MESA, Calif., Feb. 24, 2026 /PRNewswire/ -- Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand opening of its new Early Phase Center of Excellence, a state... ► Artikel lesen | |
| REGENXBIO | 7,542 | +0,45 % | REGENXBIO Inc.: Regenxbio Reports New Positive Interim Data From Phase I/ii Affinity Duchenne Trial Of Rgx-202 | Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne
Pivotal dose participants exceeded external controls across... ► Artikel lesen | |
| CORMEDIX | 6,098 | -1,29 % | CorMedix, Inc.: CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | - Q4 2025 Net Revenue of $128.6 million - Pro Forma Full Year 2025 Net Revenue of $401.3 million - Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million - Conference Call Scheduled... ► Artikel lesen |
Das Unternehmen LEXEO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -7,17 % bei einem Aktienkurs von 5,960 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXEO THERAPEUTICS INC finden Sie auf Wallstreet Online.